Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide, quantity: 50 microgram/ml - injection, solution - excipient ingredients: water for injections; mannitol; lactic acid; sodium bicarbonate - for symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy or dopamine agonist treatment. sandostatin treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: carcinoid tumours with features of the carcinoid syndrome; vasoactive intestinal peptide secreting tumours (vipomas). sandostatin is not curative in these patients. for reduction of the incidence of complications following pancreatic surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide, quantity: 500 microgram/ml - injection, solution - excipient ingredients: lactic acid; mannitol; sodium bicarbonate; water for injections - for symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy or dopamine agonist treatment. sandostatin treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: carcinoid tumours with features of the carcinoid syndrome; vasoactive intestinal peptide secreting tumours (vipomas). sandostatin is not curative in these patients. for reduction of the incidence of complications following pancreatic surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide, quantity: 30 mg - injection, modified release - excipient ingredients: polyglactin glucose; mannitol - acromegaly: for the symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment, but who are adequately controlled on subcutaneous treatment with sandostatin. sandostatin lar is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,gastro-entero-pancreatic tumours: for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - carcinoid tumours with features of the carcinoid syndrome; - vasoactive intestinal peptide secreting tumours (vipomas) in patients who are adequately controlled on subcutaneous treatment with sandostatin. sandostatin lar is not curative in these patients.,advanced neuroendocrine tumours of the midgut: treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide, quantity: 20 mg - injection, modified release - excipient ingredients: mannitol; polyglactin glucose - acromegaly: for the symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment, but who are adequately controlled on subcutaneous treatment with sandostatin. sandostatin lar is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,gastro-entero-pancreatic tumours: for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - carcinoid tumours with features of the carcinoid syndrome; - vasoactive intestinal peptide secreting tumours (vipomas) in patients who are adequately controlled on subcutaneous treatment with sandostatin. sandostatin lar is not curative in these patients.,advanced neuroendocrine tumours of the midgut: treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide, quantity: 10 mg - injection, modified release - excipient ingredients: mannitol; polyglactin glucose - acromegaly: for the symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment, but who are adequately controlled on subcutaneous treatment with sandostatin. sandostatin lar is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,gastro-entero-pancreatic tumours: for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - carcinoid tumours with features of the carcinoid syndrome; - vasoactive intestinal peptide secreting tumours (vipomas) in patients who are adequately controlled on subcutaneous treatment with sandostatin. sandostatin lar is not curative in these patients.,advanced neuroendocrine tumours of the midgut: treatment of patients with progression of well-differentiated, advanced neuroendocrine tumours of the midgut or suspected midgut origin.

Canada - English - Health Canada

paladin labs inc. - pizotifen (pizotifen malate) - tablet - 0.50mg - pizotifen (pizotifen malate) 0.50mg - antimigraine agents, miscellaneous

Ireland - English - HPRA (Health Products Regulatory Authority)

phoenix labs - pizotifen - coated tablet - 500 microgram(s) - other antimigraine preparations; pizotifen - antimigraine drug - prophylactic treatment of recurrent vascular headaches, including classical migraine, common migraine and cluster headache (periodic migrainous neuralgia). the international classification of headache disorders 2nd edition (ichd-ii) are standard classifications of headache used by healthcare professionals and describe the above-mentioned disorders as follows: prophylactic treatment of recurrent migraine headache with or without aura and of cluster headache. sanomigran is not effective in relieving migraine attacks once in progress.

Ireland - English - HPRA (Health Products Regulatory Authority)

phoenix labs - pizotifen - coated tablet - 1.5 milligram(s) - other antimigraine preparations; pizotifen - antimigraine drug - prophylactic treatment of recurrent vascular headaches, including classical migraine, common migraine and cluster headache (periodic migrainous neuralgia). sanomigran is not effective in relieving migraine attacks once in progress. the international classification of headache disorders 2nd edition (ichd-ii) are standard classifications of headache used by healthcare professionals and describe the above-mentioned disorders as follows: prophylactic treatment of recurrent migraine headache with or without aura and of cluster headache.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

novartis south africa (pty) ltd - tablet - each tablet contains pizotifen hydrogen maleate equivalent to 0,5 mg pizotifen

Israel - English - Ministry of Health

novartis israel ltd - octreotide - solution for injection / infusion - octreotide 0.1 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.